REGULATORY

Japan Approves Equa, Onglyza Generics towards December Listing, 1st DPP-4 Copycat on Horizon?

By Ken Yoshino and Shinya Sato August 19, 2024

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Japanese health ministry on August 15 granted regulatory approval for a roster of generics ahead of the next biannual generic listing to take place in December. Eight APIs saw their first generic approvals, including the DPP-4 inhibitors Equa (vildagliptin)…

To read the full story

First Generics of Equa Priced at 30% of Original Product
December 6, 2024
Xarelto, Equa Face Generic Debuts in Japan: December Listing
December 5, 2024
Xarelto Copycats Earn Blessing, AG Might also Get on Board
August 19, 2024
August Generic Approval List Includes AGs for at Least 3 APIs, Acofide and More
August 19, 2024

REGULATORY

Govt’s Honebuto Draft Confirms FY2027 Off-Year Drug Price Revision
July 1, 2026
Govt Presents Growth Strategy Draft Ahead of July Approval
July 1, 2026
Japan Moves to Add Ceftriaxone to Economic Security List
July 1, 2026
LDP Group Submits Honebuto Proposal, Urges Pediatric Cancer Platform
July 1, 2026
Lower House Clears Immunization Act Revision
July 1, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COLUMN

The Psychology of ‘Stuck’: Understanding Why Changing Jobs Feels So Hard

By Philip Carrigan

Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…